

SUVEN LIFE SCIENCES LIMITED

Unaudited Standalone Statement of Cash flows for the half year ended 30th September, 2019

(Rs.In lakhs, unless otherwise stated)

Particulars	Six months ended 30 September 2019	Six months ended 30 September 2018
<b>A. Cash flow from operating activities</b>		
Profit before tax	19,485.64	8,463.24
<b>Adjustments :</b>		
Depreciation and amortisation expense	1,346.85	1,282.07
Interest Income	(19.20)	(18.62)
Finance Cost	316.17	165.88
Gain on sale of Current Investment	(88.21)	(118.86)
Fair value gain on financial instruments at fair value through profit or loss	(113.98)	(815.41)
Loss/(Profit) on disposal of Property, plant & equipment	(8.00)	-
<b>Operating profit before working capital changes</b>	<b>20,919.27</b>	<b>8,958.29</b>
<b>Adjustments for (Increase)/decrease in operating assets</b>		
Trade Receivables	(1,260.22)	(107.24)
Inventories	478.47	(54.29)
Other non current financial assets	(10.19)	(1.03)
Other non current assets	(885.16)	(2,124.60)
Other current financial assets	(21.71)	(4.58)
Other current assets	(1,049.49)	592.37
<b>Adjustments for Increase/(decrease) in operating liabilities</b>		
Trade Payables	(1,160.21)	(1,309.45)
Long term provisions	-	13.75
Other non-current liabilities	(14.53)	(14.53)
Short term provision	119.42	53.58
Other financial liabilities	261.40	1,842.78
Other current liabilities	(194.10)	(92.73)
<b>Cash generated from operating activities</b>	<b>17,182.96</b>	<b>7,752.32</b>
Income taxes paid (net of refunds)	972.42	2,334.71
<b>Net Cash flows from operating activities</b>	<b>(A) 16,210.54</b>	<b>5,417.62</b>
<b>B. Cash flow from Investing activities</b>		
Payments for Purchase of property, plant and equipment	(3,145.31)	(3,894.92)
Proceeds from sale of Property, plant & equipment	21.43	-
Changes in Investments	(27,020.04)	(1,340.55)
Sale/(purchase) of mutual funds	13,700.00	(838.66)
Bank balances not considered as cash and cash equivalents	(2.37)	5.09
Interest received	19.20	18.62
<b>Net cash flow from / ( used in) investing activities</b>	<b>(B) (16,427.09)</b>	<b>(6,050.41)</b>
<b>C. Cash flows from financing activities</b>		
(Repayment)/Proceeds from long term borrowings	17.68	(25.36)
(Repayment)/Proceeds from short term borrowings	4,958.66	581.15
Finance Cost	(316.17)	(165.88)
<b>Net cash flow from / (used In) financing activities</b>	<b>(C) 4,660.17</b>	<b>389.91</b>
Net increase/(decrease) in cash and cash equivalents	<b>(A+B+C) 4,443.62</b>	(242.89)
Cash and cash equivalents as at the beginning of the year	1,090.74	1,342.59
<b>Cash and cash equivalents at the end of the year</b>	<b>5,534.36</b>	<b>1,099.70</b>
Cash and cash equivalents	5,534.36	1,099.70
	<b>5,534.36</b>	<b>1,099.70</b>

By Order of the Board  
Suven Life Sciences Limited

Venkateswarlu Jasti  
Chairman & CEO  
DIN: 00278028

Place : Hyderabad  
Date : 14th Nov, 2019

SUVEN LIFE SCIENCES LIMITED

Unaudited Consolidated Statement of Cash flows for the half year ended 30 September 2019

(Rs.In lakhs, unless otherwise stated)

Particulars	Six months ended 30 September 2019	Six months ended 30 September 2018
<b>A. Cash flow from operating activities</b>		
Profit before tax	15,487.06	5,767.08
<b>Adjustments :</b>		
Depreciation and amortisation expense	1,346.85	1,282.07
Interest Income	(19.20)	(18.62)
Finance Cost	397.83	166.42
Gain on sale of Current Investment	(88.21)	(118.86)
Fair value gain on financial instruments at fair value through profit or loss	(113.98)	(815.41)
Loss/(Profit) on disposal of Property, plant & equipment	(8.00)	-
<b>Operating profit before working capital changes</b>	<b>17,002.36</b>	<b>6,262.68</b>
<b>Adjustments for (Increase)/decrease in operating assets</b>		
Trade Receivables	(1,260.22)	(107.24)
Inventories	478.47	(54.29)
Other non current financial assets	(10.24)	(1.22)
Other non current assets	(885.16)	(2,124.60)
Other current financial assets	(4.08)	(4.58)
Other current assets	(1,049.49)	592.37
<b>Adjustments for Increase/(decrease) in operating liabilities</b>		
Trade Payables	(1,160.21)	(1,309.45)
Long term provisions	-	13.75
Other non-current liabilities	(14.53)	(14.53)
Short term provision	119.42	53.58
Other financial liabilities	(1,780.16)	2,635.35
Other current liabilities	(194.10)	(92.73)
<b>Cash generated from operating activities</b>	<b>11,242.06</b>	<b>5,849.09</b>
Income taxes paid (net of refunds)	972.42	2,334.71
<b>Net Cash flows from operating activities</b>	<b>(A) 10,269.64</b>	<b>3,514.39</b>
<b>B. Cash flow from Investing activities</b>		
Payments for Purchase of property, plant and equipment	(3,145.31)	(3,894.92)
Proceeds from sale of Property, plant & equipment	21.43	-
Changes in Investments	(24,675.00)	-
Sale/(purchase) of mutual funds	13,700.00	(838.66)
Foreign currency translation reserve	237.78	(42.03)
Bank balances not considered as cash and cash equivalents	(2.37)	5.09
Interest received	19.20	18.62
<b>Net cash flow from /( used in) investing activities</b>	<b>(B) (13,844.27)</b>	<b>(4,751.89)</b>
<b>C. Cash flows from financing activities</b>		
(Repayment)/Proceeds from long term borrowings	17.68	(25.36)
(Repayment)/Proceeds from short term borrowings	8,483.66	581.15
Finance Cost	(397.83)	(166.42)
<b>Net cash flow from /(used In) financing activities</b>	<b>(C) 8,103.51</b>	<b>389.36</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>	<b>(A+B+C) 4,528.88</b>	<b>(848.14)</b>
Cash and cash equivalents as at the beginning of the year	1,113.04	2,031.68
<b>Cash and cash equivalents at the end of the year</b>	<b>5,641.92</b>	<b>1,183.53</b>
Cash and cash equivalents	5,641.92	1,183.53
	<b>5,641.92</b>	<b>1,183.53</b>

By Order of the Board  
Suven Life Sciences Limited

Venkateswarlu Jasti  
Chairman & CEO  
DIN: 00278028

Place : Hyderabad  
Date : 14th Nov, 2019